Abstract: Tranilast is clinically indicated for the treatment of allergic disorders and is also a nonselective blocker of the transient receptor potential vanilloid 2 (TRPV2) channel. Previous studies have found that it has protective effects in various animal models of cardiac disease. Our laboratory has found that genetic deletion of TRPV2 results in a blunted hypertrophic response to increased afterload; thus, this study tested the hypothesis that tranilast through cardiomyocyte TRPV2 blockade can inhibit the hypertrophic response to pressure overload in vivo through transverse aortic constriction and ex vivo through isolated myocyte studies. The in vivo studies demonstrated that tranilast blunted the fibrotic response to increased afterload and, to a lesser extent, the hypertrophic response. After 4 weeks, this blunting was associated with improved cardiac function, although at 8 weeks, the cardiac function deteriorated similarly to the control group. Finally, the in vitro studies demonstrated that tranilast was not inhibiting these responses at the cardiomyocyte level. In conclusion, we demonstrated that tranilast blunting of the fibrotic and hypertrophic response occurs independently of cardiac TRPV2 channels and may be cardioprotective in the short term but not after prolonged administration.
INTRODUCTION
Tranilast is a nonselective cation channel blocker that effectively inhibits TRPV2 activation 1 in the gastrointestinal tract, 2 pancreas, 3 and heart. 4 It also inhibits TGF-b1 and platelet-derived growth factor-mediated collagen synthesis, as well as migration and proliferation of vascular smooth muscle cells. 5, 6 It is approved for clinical use in Japan and South Korea for the treatment of allergic disorders such as asthma, allergic rhinitis, and atopic dermatitis. 1 In the cardiovascular field, it was studied in the prevention of restenosis after percutaneous transluminal coronary where it was well tolerated, but was not found to be successful in decreasing the incidence of restenosis. [7] [8] [9] These basic and translational studies have led investigators to test the use of tranilast on various animal models of heart disease including hypertensive, 6 ,10 diabetic, 11, 12 and ischemic rats, 13 a canine model of atrial tachycardia, 14 and a hamster model of dilated cardiomyopathy. 4 Although these studies have shown promise for tranilast-mediated protection, not all demonstrated a positive effect. Furthermore, the precise mechanisms through which it exerts protective effects have not been clarified, but a significant number of these studies demonstrated decreased myocardial fibrosis and/or improved left ventricle (LV) remodeling.
Our laboratory has found that TRPV2 plays a crucial role in regulating calcium handling and myocyte contractility 15, 16 and others demonstrated that it also plays an integral role in maintaining cardiac structure. 17 Based on these findings, we have studied the role that TRPV2 plays in regulating the physiologic and pathologic response to increased afterload and have demonstrated that genetic TRPV2 channel deletion (TRPV2-KO) results in significantly impaired exercise tolerance 18 and a decreased hypertrophic response to transverse aortic constriction (TAC). 19 The blunting of the hypertrophic response on TRPV2 ablation was also associated with significant improvement of cardiac function and a decrease in maladaptive LV remodeling. Thus, in the current study, we sought to evaluate the therapeutic potential of tranilast as a pharmacological blocker of TRPV2 in the setting of TAC-induced pathological LV hypertrophy and remodeling because these characteristics are common in patients with heart failure with a preserved ejection fraction (HFpEF).
We demonstrate that although tranilast does decrease the development of compensatory mechanisms to increased afterload such as fibrosis and hypertrophy with improved cardiac function in the short term (4 weeks), longer treatment (8 weeks) results in LV dysfunction likely through the blunting of these same mechanisms. Furthermore, we demonstrate that these effects are unlikely to be due to direct inhibition of TRPV2 at the cardiomyocyte level, but rather seem to be independent of the actions of tranilast on the myocytes.
METHODS
All animal procedures were performed with the approval of the Institutional Animal Care and Use Committee (IACUC) of the University of Cincinnati and in accordance with the Eighth Edition of the Guide for the Care and Use of Laboratory Animals. 20 All mice were wild type (B6129FS2/ JF2 background) males 8-20 weeks of age or mice with the pore region of the TRPV2 calcium channel removed in the whole animal (TRPV2-fKO). 19, 21 TAC Surgery TAC was performed on 10-12 week old mice as previously described. 19 Briefly, the mice were intubated on isoflurane (2%-2.5% to effect), followed by an incision made in the sternal area and the sternum cut at the mid line to enter the chest cavity. The thymus was gently retracted to expose the aortic arch. After isolation of the transverse aorta between the carotid arteries, aortic constriction was performed by tying a 7-0 silk ligature against a 27 G needle, the latter being promptly removed to yield a constriction of standard size. For sham procedures, the ligature was not tied against the needle. Hemodynamic variables were measured before euthanasia at either 4 or 8 weeks after surgery.
Tranilast Oral Treatment
After TAC surgery, mice were treated with oral tranilast. Tranilast treatment, 2 mg/d (80 mg/kg), 22 was started 10 days after surgery and continued until mice were euthanized 4 or 8 weeks after surgery. The use of tranilast in this study was investigational to determine its pharmacological potential. Tranilast (Medicalchem Manufacturing Company, Touzeng Town Binhai, Yancheng City, Jiangsu Province, China) is water-insoluble, and therefore was mixed in low-fat peanut butter (Better'n Peanut Butter; Wonder Natural Foods Corporation, Watermill, NY), and fed to the mice once a day. TAC control and sham mice were given equivalent amounts of low-fat peanut butter containing no tranilast.
Invasive Blood Pressure
Invasive blood pressure measurements were performed on the TAC mice before euthanization as previously described 16 with isoflurane (2% to effect) as the anesthetic. Briefly, the right femoral artery was cannulated and connected to a low-compliance pressure transducer (COBE Cardiovascular, Arvada, CO). A high-fidelity, 1.2-French SciSence pressure catheter (SciSence, London, ON, Canada) was inserted into the right carotid artery and advanced into the LV to monitor cardiac performance. Hemodynamic variables were collected and analyzed using a MacLab 4/S system (AD Instruments, Colorado Springs, CO) and Chart Software. After euthanasia, body weights (BWs) were taken, whole hearts dissected out and weighed to estimate heart weight/ body weight (HW/BW) ratio. The hearts were then cut longitudinally, half was fixed with formaldehyde for histopathological analysis and half was flash frozen in N 2 for molecular studies.
Histopathology
Hearts were formalin-fixed, routinely processed, paraffin-embedded, and cut into 6-mm sections by the CCHMC Department of Pathology Research Core (Cincinnati, OH), and individually stained with Masson's Trichrome (Masson Trichrome Stain Kit; Thermo Scientific, Kalamazoo, MI). Briefly, 10 nonoverlapping photomicrographs were taken for each mouse heart (Olympus 1X71; Olympus, Melville, NY) and then randomized before analysis. Quantification of Masson Trichrome-stained sections was performed through color-based thresholding assisted by ImageJ (NIH), as previously described. 19 
Echocardiography
Echocardiography measurements were taken at baseline and at the conclusion of the 4-week study; the 8-week study had echocardiograms on a biweekly basis. All echocardiographic studies were performed as previously described. 21 Briefly, mice were anesthetized with isoflurane (2.5%) and placed on the heated stage of the Vevo 2100. Parasternal long axis and short axis images were recorded and then analyzed on a separate work station with VevoStrain software (Vevo 2100, v1.6, VisualSonics, Toronto, ON, Canada). From the M-mode images, left ventricular cavity size for systole and diastole (LV Vol; s and LV Vol; d, respectively) as well as wall thickness of the intraventricular septum and posterior wall (IVS and PW, respectively) were measured and ejection fraction (%EF) was calculated using the Vevo software.
Cardiomyocyte Contractility
Ventricular myocytes from sham and 4-week post-TAC mouse hearts were enzymatically dissociated using Langendorff perfusion as previously described. 21, 23 Myocytes were placed in a plexiglass cell chamber filled with Tyrode solution containing 1.8 mM CaCl 2 at room temperature (248C). The solution also contained either vehicle or the indicated treatment drugs, at a concentration of 1 mM for probenecid and 100 mM for tranilast. Myocytes were excited with field stimulation (Grass S48 stimulator; Grass Instruments, Quincy, MA) with 2 milliseconds 1.5· threshold pulses at a rate of 1 Hz. Steady-state myocyte shortening was imaged using a CCD camera and examined using a video-edge detector (Crescent Electronics, Sandy, UT). Data were sampled through an Axon Digidata 1322A board using the PCLAMP 9 software (both by Molecular Devices, Sunnyvale, CA).
Neonatal Rat Ventricular Myocyte Isolation and Cell Culture
Neonatal rat ventricular myocytes (NRVMs) were isolated as previously described. 24 Briefly, hearts were removed from Sprague-Dawley rats that were 1-2 days old, atria were removed, the ventricles were cut into small pieces and digested first in 0.05% trypsin/EDTA (Corning, Corning, NY) overnight, and then in collagenase II (Gibco; Thermo Fisher, Waltham, MA) for 30 minutes. Cells were then spun at 100 · g followed by a 40-minute preplating process on nontreated plates to allow the fibroblasts to adhere. The nonadherent NRVMs were then transferred to cell culture-treated dishes in MEM alpha media (Gibco; Thermo Fisher) with 10% FBS.
RNA Isolation and qRT-PCR
Total RNA was isolated from whole mouse hearts (Qiazol method; Qiagen, Venlo, Limburg, the Netherlands) and cDNA was synthesized (High-Capacity RNA-to-cDNA kit; Applied Biosystems, Carlsbad, CA). Samples were run on Stratagene Mx3005P (Agilent Technologies, Santa Clara, CA) using ABsolute Blue qPCR Mix, SYBR Green, ROX (Thermo Scientific, Kalamazoo, MI). Primer sequences are listed in Table 1 .
NRVM RNA was isolated using a Macherey-Nagel NucleoSpin RNA kit (Takara Bio USA, Inc, Düran, Germany) and cDNA was synthesized using a BioScript All-in-One cDNA Synthesis SuperMix (Biotool; Stratech Scientific Limited, Suffolk, United Kingdom). Samples were run on Stratagene Mx3005P (Agilent Technologies) using SYBR Green qPCR Master Mix (Biotool; Stratech Scientific Limited) to assess levels of GAPDH and ANF. Results were analyzed using the DDCt method. 25 Primer sequences are listed in Table  1 . Cells were treated with 10 mM phenylephrine (PE6tranilast; 100 mM) for 24 hours to induce hypertrophic signaling.
NFAT-Luciferase Reporter Assays
NRVMs were transfected with 75 ng per well (in a 96-well plate) of NFAT-luciferase reporter plasmid acquired from Addgene (Cambridge, MA). 26 Twenty-four hours after transfection, cells were treated with 10 mM phenylephrine (6tranilast; 100 mM) for 24 hours. To quantify luciferase reporter expression, cells were rinsed with sterile PBS and then lysed with 50 mL cell lysis buffer (Promega, Madison, WI) for 5 minutes at room temperature, followed by addition of 100 mL luciferase assay reagent (Promega), and luminescence was read immediately using a Cytation 5 (BioTek, Winooski, VT).
Data Analysis
Statistical analysis was performed by 1-way analysis of variance (ANOVA), 2-way ANOVA, or 2-way repeatedmeasures ANOVA as appropriate. Where significance was indicated, post hoc testing was performed using the HolmSidak method for comparing individual mean values and correcting for family-wise error (SigmaPlot v.13.0; Systat Software, Inc, San Jose, CA). Data are presented as mean 6 SEM, and differences are regarded as significant at P # 0.05.
RESULTS

Four-Week Treatment With Tranilast Preserves Cardiac Function in Response to
Increased Afterload TRPV2-KO mice have a blunted response to TAC; 19 thus, we sought to establish whether this lack of hypertrophy would be seen in wild-type (WT) mice treated with tranilast. We induced TAC on 30 WT and sham procedure on 14 mice. Immediately after TAC, mice were randomized to control (N = 13) or tranilast (N = 17). At 4-week post-TAC, invasive blood pressure revealed augmented systolic and diastolic function (as measured by the maximum and minimum rate of contraction) in the TAC tranilast group in comparison with the TAC control group (Fig. 1A and B) (P , 0.05 for TAC tranilast compared with sham and TAC). Furthermore, function was higher in the treated mice in comparison with sham mice, likely due to the observed hypertrophic response. Echocardiographic measures of cardiac function when compared with baseline demonstrated a similar pattern because the decrease in EF was worse in the TAC group compared with the TAC tranilast group (Fig. 1C, P , 0 .05 for TAC 4 weeks compared with TAC baseline), although the degree of LV cavity dilation was worse in the treatment group (Fig. 1D , P , 0.05 for TAC tranilast 4 weeks compared with baseline).
Four-Week Treatment With Tranilast Blunts the Hypertrophic and Fibrotic Response to Increased Afterload
The development of hypertrophy in response to TAC was blunted in the tranilast-treated group as measured via posterior wall thickness during diastole and LV mass/BW ratio (Figs. 2A, B) . Anterior wall thickness demonstrated a similar trend (data not shown). These findings were consistent with the traditional ex vivo measurement of HW/BW ratio ( Fig. 2C ; P , 0.05 compared with sham). There was a nonsignificant decrease in HW:BW ratio between TAC and TAC tranilast. Histological analysis demonstrated that the percent of fibrotic tissue in the tranilast-treated group was significantly lower than in the nontreated cohort (Figs. 2D, E, P , 0.05). These studies suggest that tranilast treatment can blunt the development of hypertrophy and fibrosis and preserve cardiac function in the short term.
Eight-Week Treatment With Tranilast did Not Preserve Cardiac Function in Response to Increased Afterload
To establish if the blunting of the hypertrophic and fibrotic response after 4 weeks of tranilast was protective over a longer period, we induced TAC on 22 WT and sham procedure on 6 WT mice. Thirteen TAC mice were randomized to tranilast and 9 to vehicle treatment for 8 weeks with echocardiographic studies performed on all at baseline and every 2 weeks. In contrast to the short-term study, invasive catheterization demonstrated no significant difference in systolic and diastolic function between the TAC and TAC tranilast groups as measured by dP/dt max and dP/dt min (Figs.  3A, B) . Furthermore, although there was a nonsignificant trend toward improved function in the tranilast-treated group at 6 and 8 weeks, both groups showed a similar decrease in Fig. 3C ; P , 0.05 TAC compared with sham) and increase in LV cavity dilation ( Fig. 3D ; P , 0.05 TAC tranilast compared with sham at 6 and 8 weeks).
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Eight-Week Treatment With Tranilast Blunts the Hypertrophic and Fibrotic Response to Increased Afterload
Despite the blunted hypertrophic response that was observed at 2 and 4 weeks in the tranilast group, after 8 weeks, there was no significant difference in hypertrophy between the TAC and TAC tranilast groups as measured via posterior wall thickness ( Fig. 4A ; P , 0.05 for sham compared with TAC and sham compared with TAC tranilast), LV mass/BW ( Fig. 4B ; P , 0.05 for sham compared with TAC and sham compared with TAC tranilast), or HW/BW ratio (Fig. 4C) (P , 0.05 compared with sham) . Through histology, we observed significantly decreased fibrosis in the tranilast-treated group (Figs. 4D, E; P , 0.05 TAC tranilast compared with TAC). Thus, these studies show that although short-term inhibition of the hypertrophic and fibrotic response may preserve cardiac function, longer-term blunting of these compensatory mechanisms results in similar degree of cardiac dysfunction and dilation.
Tranilast Treatment in TRPV2-fKO Mice has No Effect on Hypertrophy
In addition to the WT surgeries, 4 WT mice underwent sham surgery and 8 TRPV2-fKO mice underwent TAC surgery. These control mice were fed tranilast for 4 (sham) and 8 weeks (TAC). The 4-week WT sham tranilast mice had an average LV mass/BW of 3.01 6 0.24 at baseline and 2.84 6 0.14 at 4 weeks after surgery. These values were not statistically different from the 4-week WT sham untreated mice, 3.11 6 0.16 (P = 0.71) and 3.03 6 0.11 (P = 0.32), respectively (Fig. 2B) . The LV mass/BW values of the TRPV2-fKO TAC tranilast-treated mice were also not statistically different at baseline (3.23 6 0.18) or at 8-week post-TAC (2.93 6 0.33) from the TRPV2-fKO TAC mice previously published at baseline (3.23 6 0.25; P = 0.99) and at 8-week post-TAC (3.67 6 0.18, P = 0.16). 19 
Tranilast Blunted TGF-b1 Expression at 4 but Not 8 Weeks of Treatment
We measured various markers of fibrosis and fibrotic signaling at 4 and 8 weeks after TAC. We found that at 4 weeks, the mRNA expression level of TGF-b1 was the only one blunted by tranilast treatment. CTGF trended to increase after TAC and was significantly increased with tranilast treatment. Col3A1 and FN1 were both significantly increased in the TAC and the TAC tranilast groups (Fig. 5A) . Regarding the 8-week data, TGF-b1 trended higher in the TAC group and was significantly increased in TAC tranilast group; however, CTGF, Col3A1, and FN1 were statistically higher in both TAC and TAC tranilast groups in comparison with sham (Fig. 5B) .
Tranilast Does Not Affect TRPV2-Induced Cardiomyocyte Contractile Function Under Baseline or Hypertrophic Conditions
We examined whether the observed in vivo effects of tranilast were mediated by its direct effects on TRPV2 in cardiomyocytes. After stimulation with probenecid, a known TRPV2 agonist, isolated myocytes from both sham and TAC mice (4 weeks) exhibited an increase in fractional shortening (P , 0.05 for probenecid vs. control for sham and TAC), although the TAC myocytes demonstrated significantly higher contractility consistent with greater TRPV2 activity (Fig.  6A , middle columns; P , 0.05 TAC probenecid compared with sham probenecid). Interestingly, pretreatment with tranilast did not cause significant changes in probenecid-induced contractility in either the TAC or sham mice (Fig. 6A middle  and right columns) . Thus, these data suggest that tranilast does not seem to be significantly altering the myocyte response to a known, potent TRPV2 agonist. Similarly, treatment with probenecid significantly increased myocyte shortening rate (dL/dt max , 6B) in both sham and TAC myocytes and increased the relengthening rate (dL/dt min , 6C) in TAC myocytes compared with controls (P , 0.05 compared with control). Treatment with both probenecid and tranilast had the same shortening and relengthening rates in sham and TAC myocytes as probenecid alone.
Tranilast Does Not Directly Affect Myocyte Hypertrophic Signaling
To further determine whether the observed hypertrophy-reducing effects of tranilast were due to direct actions on myocytes, we used an in vitro model of myocyte hypertrophy using phenylephrine (PE) treatment of primary NRVMs as previously described. 24 Results showed that tranilast did not inhibit PE-induced (10 mM for 24 hours) expression of ANF, a known gene marker of cardiac hypertrophy ( Fig. 6D ; P , 0.05 compared with control). We also observed similar results with the inability of tranilast to reduce PE-induced transcriptional activation of NFAT ( Fig.  6E ; P , 0.05 compared with control).
DISCUSSION
In this study, we found that tranilast modulated the fibrotic, and to a lesser extent the hypertrophic, response to pathological stress. Hemodynamically, the blunting of these responses preserved cardiac function over a 4-week period, but not 8-week period, after TAC-induced LV pressure overload. This effect did not seem to be mediated by a direct effect on the cardiac myocytes and was at least partially mediated by decreased development of fibrosis.
Tranilast has been tested in a number of cardiac disease animal models with varying results. For example, Betge et al evaluated late-onset oral treatment with tranilast after large myocardial infarction in rats where they treated the animals with tranilast 28 days after an induced myocardial infarction in the rat. There was no significant difference in survival rate and collagen content in the tranilast-treated rats compared with the control group. 27 The studies that have found a positive effect of tranilast on the development of cardiomyopathy used animal models of diabetic 11, 12 and dilated cardiomyopathy. 4 The former focused on the effects of tranilast on TGF-b signaling, whereas the latter concluded that its effect was secondary to removal of sarcolemmal TRPV2 with a subsequent reduction in the phosphorylation of calmodulin-dependent protein kinase II (CaMKII). These studies demonstrated reduced development of fibrosis as the likely direct factor influencing the improved cardiac outcomes. Similarly, our laboratory previously demonstrated that TAC induced TRPV2 upregulation and translocation, whereas the functional deletion of TRPV2 reduced the development of myocyte hypertrophy and fibrosis. 19 This was consistent with a study by Ward et al 22 that found that tranilast treatment affected the expression levels of TGF-b isoforms in rats after arterial injury in a dosedependent manner. Our study into the expression of various markers of fibrosis indicated that tranilast was also able to decrease TGF-b1 expression 4 weeks, but not 8 weeks, after TAC.
This study adds a translational component to the body of literature regarding TRPV2 and the role of tranilast in the development of hypertrophy and fibrosis in animal models, and it is the first one to test the role of tranilast in a TAC model and to evaluate its effects over different periods. Although TAC is an appropriate model to induce hypertrophy, there are other models of hypertrophy that have also tested the use of tranilast. Umemura et al 10 administered tranilast for 4 weeks to spontaneously hypertensive rats and assessed the impact on the cardiac collagen matrix associated with increased myocardial stiffness. Consistent with our findings, they demonstrated that tranilast treatment significantly suppressed increases in LV collagen concentration and LV weight/BW ratios in the spontaneously hypertensive rats while not affecting systolic blood pressure, diastolic blood pressure, heart rate, or cardiac output.
This study confirms the positive effects of tranilast on cardiac function and remodeling over a 4-week period, but brings into question the long-term use of tranilast in pressure overload conditions. The observed blunting of the compensatory mechanisms in response to pressure overload in this study appear to result in positive short-term, but not long-term, effects on cardiac function. This is likely secondary to the need of the myocardium to develop hypertrophy and/or dilation to overcome the higher pressures as per Laplace's law, where increased wall thickness and/or dimensions are required to maintain physiologic pressure in response to increased tension (ie, afterload). 28 The implications of this finding are important, as the inhibition of left ventricular hypertrophy is a potential target for preventing the development of HFpEF. Unfortunately, to date no drug specific therapy has been taken to the bedside for this indication. [7] [8] [9] The pathophysiology underlying HFpEF is related to abnormalities in diastolic function due to relaxation and ventricular stiffness associated with development of left ventricular hypertrophy and development of fibrosis. Tranilast has been studied regarding its effect on fibrosis by Hocher et al who used tranilast in rats with renovascular hypertension. In that study, tranilast did not alter blood pressure, but using a computer-aided image analysis system, it was demonstrated that tranilast had an effect on preventing cardiac fibrosis and attenuating left ventricular fibrosis, most likely due to the decrease in the proliferation of cardiac nonmyocyte cells. 4 Furthermore, Martin et al evaluated the role of tranilast in cardiac matrix deposition in cultured cardiac fibroblasts and then assessed effects on diabetic rats. They demonstrated a 58% reduction in TGF-b1 induced 3
[H]-hydroxyproline incorporation with high-dose tranilast (400 mg/kg). In addition, after 16 weeks, the control rats showed increased cardiac fibrosis and evidence of TGF-b1 activation compared with those given tranilast, which, despite persistent hyperglycemia and hypertension, had attenuated cardiac fibrosis in association with a reduction of TGF-b1 activation. 12 Finally, this study suggests that tranilast has no significant direct effect on myocyte function or hypertrophic signaling in vitro. Our previous work demonstrated that a functional TRPV2 genetic deletion also inhibits the development of hypertrophy in response to TAC, but the deletion model used was not myocyte-specific. 19 Thus, in light of these current findings, it seems that tranilast's blunting of cardiac hypertrophy and fibrosis are at least partially mediated by non-myocyte-specific effects. Elucidation of the full mechanisms by which tranilast mediates cardiac fibrosis is beyond the scope of this body of work, but, future studies will identify the role of TRPV2 in cardiac fibroblasts, myocyte-fibroblast interactions, and extracellular matrix production.
CONCLUSION
In summary, this study demonstrates that short-term blunting of cardiac fibrosis in response to increased afterload with tranilast has beneficial effects that are not sustained after longer-term therapy. Furthermore, these effects do not seem to be mediated by the drug's effects on TRPV2 in the cardiomyocyte. Regardless of the mechanism of action, we show that tranilast may be an appropriate therapeutic option for the prevention of cardiac dysfunction associated with HFpEF.
